Trading Signals: FOLD Stock Price Prediction and Forecast (Thu. May. 31, 2007 - Fri. Dec. 22, 2023)(Amicus Therapeutics Inc)
| FOLD latest price $11.4950 (-1.5%) ($11.4950 - $11.4950) on Thu. Apr. 20, 2023. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 2.1% (three month average) | RSI | 61 | Latest Price | $11.4950(-1.5%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | FOLD declines -0.2% a day on average for past five trading days. | Weekly Trend | FOLD advances 2.9% a week on average for past two weeks. | Market Behavior | Broad based sell-off for large cap. Value stock sell-off for small cap. | Correlated ETFs | Broad market will support FOLD advance at 0% a week (0% probability) XBI(60%) IBB(57%) IWO(45%) IWM(44%) IWC(42%) | Factors Impacting FOLD price | FOLD will decline at least -1.05% in a week (0% probabilities). TBT(-22%) VXX(-15%) UUP(-12%) VIXM(-6%) BNDX(-6%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.05% (StdDev 2.1%) | Hourly BBV | -1.6 () | Intraday Trend | 0% | | | |
|
5 Day Moving Average | $11.67(-1.5%) | 10 Day Moving Average | $11.46(0.31%) | 20 Day Moving Average | $11.28(1.91%) | To recent high | -15.8% | To recent low | 5.2% | Market Cap | $2.968b | | | | Amicus Therapeutics, Inc. is a biotechnology company focused on discovering, developing, and delivering medicines for people living with rare metabolic diseases. The company is committed to advancing and expanding a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. Amicus Therapeutics has a portfolio of product opportunities including the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants; a novel, clinical-stage, treatment paradigm for Pompe disease; and a rare disease gene therapy portfolio. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ. |